According to a recent LinkedIn post from ENA Respiratory, the company has added Melissa Faris to its board as an independent non-executive director. The post highlights her extensive background in respiratory disease business development across pharma and biotech.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post notes that Faris currently serves as Chief Business Officer at U.K.-based OMass Therapeutics and previously spent two decades at GSK in senior roles. Her experience spans clinical development and business development for respiratory and immunology medicines from Phase 1 through registration and launch.
For investors, the appointment suggests ENA Respiratory is strengthening its governance and deal-making capabilities as it advances antiviral and respiratory drug programs. The addition of a board member with end-to-end development and partnering expertise could support future licensing, collaborations, or capital-raising efforts in a competitive respiratory therapeutics landscape.